Site by Pixelstream
In this issue:
+ CIPP to launch capacity building training programs in 2007
+ CIPP launches web-based "IP Reading Guide"
+ CIPP awarded CIHR funding
+ CIPP part of a new research project at McMaster University
+ Bristol-Myers holds Canadian patients hostage, by Richard Gold
+ Intellectual Property Biotechnology Capacity and Development, Workshop, September 25-27, 2006, Buenos Aires
To meet its vision of community service, the CIPP and its Kenyan partners will be launching a series of intellectual property training courses in Kenya in the Winter of 2007. These courses will ensure that key players in Kenya receive appropriate and required training in intellectual property and intellectual property management and that CIPP's intellectual property policy research is disseminated to a large scale audience. The courses will target local business people, researchers and scientists, as well as government officials dealing with intellectual property issues.
Our local partners in Kenya include the University of Nairobi, the Kenyan Intellectual Property Institute, the International Center of Insect Physiology and Ecology, and the Southern Environmental and Agricultural Policy Research Institute.
CIPP's bottom-up approach to capacity building is unique in that it takes into account local particularities to leave behind a legacy of not only greater capacity in innovation and development, but a pool of locally trained decision makers and business people equipped to work with the developed world. This approach differentiates the CIPP from other organizations that simply export domestic approaches.
There is a strong demand for the Kenyan project and such initiatives will play an important role in building a sustainable Africa. We are currently seeking funds to make the Kenyan project a success and welcome donations in this regard. Donations can be made by contacting Tal Srulovicz, Acting Executive Director at (514) 398-2761 or by email at email@example.com.
The Centre for Intellectual Property Policy welcomes you to the IP Reading Guide, a reference of intellectual property material for academics, students, policy makers and business people. The IP Reading Guide contains legislation, leading IP cases, recommendations, guidelines and policy reports, as well as articles and books in all areas of intellectual property. This tool is part of CIPP's mission to facilitate debate about intellectual property issues around the world.
To access CIPP's IP Reading Guide, click here.
"Intellectual Property Governance and Non-State Actors: The Case of Bill C-9" is a research project funded by the Canadian Institutes of Health Research as a sub-project of the CIPP's Intellectual Property Modeling Group Project. This project will provide policy-makers and researchers with a greater understanding of how best to bring concerned citizens, non-governmental organizations and industry associations into decision-making around healthcare innovation. It will do so by examining the role of a group of citizens, non-governmental organizations and industry associations in bringing about one of Canada's most recent and novel contributions to Canadian and international health care: Parliament's passage of Bill C-9 that permits the government to give licenses to pharmaceutical companies to manufacture and sell medicines to developing and least developed countries facing health crises despite the existence of a patent held by someone else.
For additional information on this research project, click here.
CIPP Director Richard Gold is co-investigator on a project entitled "Balancing Innovation and Access in Health Biotechnology: The Roles and Responsibilities of Innovators", funded by the Canadian Institutes of Health Research. This project, headed by Fiona Miller at McMaster University, aims to examine the role of health biotechnology in the creation of innovations which simultaneously generate economic wealth and successfully treat health conditions. Richard Gold brings his expertise in intellectual property policy research to the interdisciplinary team of researchers involved with this project.
Bristol-Myers Squibb Canada’s ability to prevent the distribution of its anti-cancer drug, Erbitux, illustrates what is wrong with Canadian patent-law. In doing so, it is not only acting in bad faith with respect to Canadian patients, but is breaking its deal with the Canadian government.
This Workshop will bring together international policy-makers, academics and non-state actors to discuss how to configure intellectual property laws, business and governmental practices, and private and public institutions to encourage the development of biotechnological research and development capacity in developing countries and in disadvantaged communities in developed countries. Many argue that intellectual property is an important tool in addressing health and food concerns in developing countries. However, history suggests that developing countries and disadvantaged communities cannot rely on richer countries and communities to address their particular concerns. One option available to developing countries and disadvantaged communities is to develop local expertise and infrastructure in biotechnology. This two-day Workshop will explore the ways that intellectual property law, business and governmental practice, and private and public institutions can assist in this effort.
For additional information on this event, click here.